SAFETY DATA SHEET
Abamectin Liquid Formulation

Section 1. Identification

Product name: Abamectin Liquid Formulation
Other means of identification: No data available

Manufacturer or supplier's details
Company name of supplier: Merck & Co., Inc
Address: 126 E. Lincoln Avenue, Rahway, New Jersey U.S.A. 07065
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product
Restrictions on use: Not applicable

Section 2. Hazards Identification

GHS classification in accordance with the Hazardous Products Regulations
Acute toxicity (Inhalation): Category 4
Reproductive toxicity: Category 2
Specific target organ toxicity - repeated exposure (Oral): Category 1 (Central nervous system)
Specific target organ toxicity - repeated exposure: Category 2 (Central nervous system)

GHS label elements
Hazard pictograms:

Signal Word: Danger

Hazard Statements:
H332 Harmful if inhaled.
H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H372 Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Precautionary Statements:
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.

Date of last issue: 10/01/2022
Date of first issue: 01/18/2017

Date of last issue: 10/01/2022
Date of first issue: 01/18/2017
SAFETY DATA SHEET

Abamectin Liquid Formulation

Version 4.11  Revision Date: 04/04/2023  SDS Number: 1219529-00019  Date of last issue: 10/01/2022  Date of first issue: 01/18/2017

P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a doctor if you feel unwell.
P308 + P313 IF exposed or concerned: Get medical attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Common Name/Synonym</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rape oil</td>
<td>No data available</td>
<td>8002-13-9</td>
<td>&gt;= 60 - &lt; 80 *</td>
</tr>
<tr>
<td>abamectin (combination of avermectin B1a and avermectin B1b) (ISO)</td>
<td>No data available</td>
<td>71751-41-2</td>
<td>&gt;= 1 - &lt; 5 *</td>
</tr>
</tbody>
</table>

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact:
Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed:
If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
Harmful if inhaled.
Suspected of damaging fertility. Suspected of damaging the unborn child.
Causes damage to organs through prolonged or repeated exposure if swallowed.
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders:
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician:
Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media:
Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media:
None known.

Specific hazards during fire fighting:
Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
Carbon oxides

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters:
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for:
Soak up with inert absorbent material.
containment and cleaning up For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling : Do not breathe mist or vapors. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage : Keep in properly labeled containers. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.
Materials to avoid : Do not store with the following product types: Strong oxidizing agents Self-reactive substances and mixtures Organic peroxides Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Ingredients with workplace control parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Components</td>
</tr>
<tr>
<td>Rape oil</td>
</tr>
<tr>
<td>abamectin (combination of avermectin B1a and avermec-</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
Abamectin Liquid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.11</td>
<td>04/04/2023</td>
<td>1219529-00019</td>
<td>10/01/2022</td>
<td>01/18/2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>tin B1b) (ISO)</th>
<th>Wipe limit</th>
<th>Internal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>150 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

**Engineering measures**: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

**Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type**

**Hand protection**

**Material**: Chemical-resistant gloves

**Remarks**: Consider double gloving.

**Eye protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**

**Work uniform or laboratory coat**

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

**Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

**Appearance**: liquid

**Color**: light yellow

**Odor**: characteristic
### Odor Threshold
No data available

### pH
No data available

### Melting point/freezing point
No data available

### Initial boiling point and boiling range
No data available

### Flash point
No data available

### Evaporation rate
No data available

### Flammability (solid, gas)
Not applicable

### Flammability (liquids)
No data available

### Upper explosion limit / Upper flammability limit
No data available

### Lower explosion limit / Lower flammability limit
No data available

### Vapor pressure
No data available

### Relative vapor density
No data available

### Relative density
No data available

### Density
0.90 - 0.94 g/cm³

### Solubility(ies)
- **Water solubility**: insoluble

### Partition coefficient: n-octanol/water
Not applicable

### Autoignition temperature
No data available

### Decomposition temperature
No data available

### Viscosity
- **Viscosity, kinematic**: No data available

### Explosive properties
Not explosive

### Oxidizing properties
The substance or mixture is not classified as oxidizing.

### Molecular weight
No data available

### Particle size
Not applicable

---

**SECTION 10. STABILITY AND REACTIVITY**
### Reactivity
Not classified as a reactivity hazard.

### Chemical stability
Stable under normal conditions.

### Possibility of hazardous reactions
Can react with strong oxidizing agents.

### Conditions to avoid
None known.

### Incompatible materials
Oxidizing agents

### Hazardous decomposition products
No hazardous decomposition products are known.

## SECTION 11. TOXICOLOGICAL INFORMATION

### Information on likely routes of exposure

**Inhalation**

**Skin contact**

**Ingestion**

**Eye contact**

### Acute toxicity
Harmful if inhaled.

**Product:**

- **Acute oral toxicity:** Acute toxicity estimate: > 2,000 mg/kg
  - Method: Calculation method

- **Acute inhalation toxicity:** Acute toxicity estimate: 2.3 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist
  - Method: Calculation method

- **Acute dermal toxicity:** Acute toxicity estimate: > 2,000 mg/kg
  - Method: Calculation method

### Components:

**Rape oil:**

- **Acute oral toxicity:** LD50 (Rat): > 2,000 mg/kg
- **Acute dermal toxicity:** LD50 (Rat): > 2,000 mg/kg

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

- **Acute oral toxicity:** LD50 (Rat): 24 mg/kg
  - LD50 (Mouse): 10 mg/kg
  - LDLo (Monkey): 24 mg/kg
  - Symptoms: Dilatation of the pupil
- **Acute inhalation toxicity:** LC50 (Rat): 0.023 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist
- **Acute dermal toxicity:** LD50 (Rat): 330 mg/kg
  - LD50 (Rabbit): 2,000 mg/kg
## Skin corrosion/irritation
Not classified based on available information.

### Components:

**Rape oil:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>No skin irritation</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>No skin irritation</td>
</tr>
</tbody>
</table>

### Serious eye damage/eye irritation
Not classified based on available information.

### Components:

**Rape oil:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>No eye irritation</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Mild eye irritation</td>
</tr>
</tbody>
</table>

## Respiratory or skin sensitization

### Skin sensitization
Not classified based on available information.

### Respiratory sensitization
Not classified based on available information.

### Components:

**Rape oil:**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Human repeat insult patch test (HRIPT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routes of exposure</td>
<td>Skin contact</td>
</tr>
<tr>
<td>Species</td>
<td>Humans</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Maximization Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routes of exposure</td>
<td>Skin contact</td>
</tr>
<tr>
<td>Result</td>
<td>Not a skin sensitizer.</td>
</tr>
</tbody>
</table>
Germ cell mutagenicity
Not classified based on available information.

Components:

Rape oil:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Result: negative
Remarks: Based on data from similar materials

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo:
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Species: Rat
Application Route: Oral
Exposure time: 105 weeks
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 93 weeks
Result: negative

Reproductive toxicity
Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:

Rape oil:
Effects on fertility: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials

Effects on fetal development: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):


Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Early Embryonic Development: NOAEL: 0.12 mg/kg body weight Result: Fetotoxicity.

Effects on fetal development: Test Type: Embryo-fetal development Species: Mouse Application Route: Oral General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight Developmental Toxicity: NOAEL: 0.2 mg/kg body weight Result: Cleft palate Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 2 mg/kg body weight Result: Cleft palate, Teratogenic effects., Reduced embryonic survival Remarks: Adverse developmental effects were observed

Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 1.6 mg/kg body weight Result: Teratogenic effects.

Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal
STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

- **Routes of exposure**: Ingestion
- **Target Organs**: Central nervous system
- **Assessment**: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

**Components:**

- **Rape oil:**
  - **Species**: Rat
  - **NOAEL**: > 100 mg/kg
  - **Application Route**: Ingestion
  - **Exposure time**: 90 Days
  - **Remarks**: Based on data from similar materials

- **abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**
  - **Species**: Rat
  - **NOAEL**: 1.5 mg/kg
  - **Application Route**: Oral
  - **Exposure time**: 24 Months
  - **Target Organs**: Central nervous system
  - **Symptoms**: Tremors, ataxia
  - **Species**: Mouse
  - **NOAEL**: 4.0 mg/kg
  - **Application Route**: Oral
  - **Exposure time**: 24 Months
  - **Target Organs**: Central nervous system
  - **Symptoms**: Tremors, ataxia
  - **Species**: Dog
  - **NOAEL**: 0.25 mg/kg
  - **LOAEL**: 0.5 mg/kg
  - **Application Route**: Oral
  - **Exposure time**: 53 Weeks
  - **Target Organs**: Central nervous system
  - **Symptoms**: Tremors, weight loss
  - **Remarks**: mortality observed
  - **Species**: Monkey
NOAEL: 1.0 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Central nervous system

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Ingestion: Symptoms: May cause, Tremors, Diarrhea, central nervous system effects, Salivation, tearing

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:
Rape oil:
Toxicity to fish: LL50 (Danio rerio (zebra fish)): > 100 mg/l
Exposure time: 96 h
Method: ISO 7346/1
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 96.72 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EL50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

NOELR (Desmodesmus subspicatus (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms: NOEC (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Remarks: Based on data from similar materials

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
Exposure time: 96 h
SAFETY DATA SHEET

Abamectin Liquid Formulation

Version 4.11 Revision Date: 04/04/2023 SDS Number: 1219529-00019 Date of last issue: 10/01/2022 Date of first issue: 01/18/2017

LC₅₀ (Ictalurus punctatus (channel catfish)): 24 µg/l Exposure time: 96 h
LC₅₀ (Cyprinus carpio (Carp)): 42 µg/l Exposure time: 96 h
LC₅₀ (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates:
EC₅₀ (Americamysis): 0.022 µg/l Exposure time: 96 h
EC₅₀ (Daphnia magna (Water flea)): 0.34 µg/l Exposure time: 48 h

Toxicity to algae/aquatic plants:
EC₅₀ (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h

Toxicity to fish (Chronic toxicity):
NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l Exposure time: 32 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 0.03 µg/l Exposure time: 21 d
NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l Exposure time: 28 d

Toxicity to microorganisms:
EC₅₀: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition

Persistence and degradability

Components:
Rape oil:
Biodegradability: Result: Readily biodegradable.
Remarks: Based on data from similar materials

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Stability in water: Hydrolysis: 50 % (< 12 h)

Bioaccumulative potential

Components:
Rape oil:
Partition coefficient: n-octanol/water: log Pow: > 4
Remarks: Expert judgment

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):
Bioaccumulation: Bioconcentration factor (BCF): 52
Partition coefficient: n-octanol/water  
\[ \text{log Pow: 4} \]

Mobility in soil

Components:

**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Distribution among environmental compartments  
\[ \text{log Koc: > 3.6} \]

Other adverse effects

No data available

### SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues  
Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging  
Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

### SECTION 14. TRANSPORT INFORMATION

**International Regulations**

**UNRTDG**

UN number  
UN 3082

Proper shipping name  
ENVIROMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO))

Class  
9

Packing group  
III

Labels  
9

**IATA-DGR**

UN/ID No.  
UN 3082

Proper shipping name  
Environmentally hazardous substance, liquid, n.o.s.  
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO))

Class  
9

Packing group  
III

Labels  
Miscellaneous

Packing instruction (cargo aircraft)  
964

Packing instruction (passenger aircraft)  
964

Environmentally hazardous  
yes

**IMDG-Code**

UN number  
UN 3082

Proper shipping name  
ENVIROMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
SAFETY DATA SHEET

Abamectin Liquid Formulation

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

TDG
UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO))

Class : 9
Packing group : III
Labels : 9
ERG Code : 171
Marine pollutant : yes (abamectin (combination of avermectin B1a and avermectin B1b) (ISO))

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations
CA QC OEL : Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
CA QC OEL / TWAEV : Time-weighted average exposure value

AIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with
SAFETY DATA SHEET

Abamectin Liquid Formulation

Version 4.11  Revision Date: 04/04/2023  SDS Number: 1219529-00019  Date of last issue: 10/01/2022

Sources of key data used to compile the Material Safety Data Sheet:


Revision Date: 04/04/2023

Date format: mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8